Light chains are proteins produced by immune cells called plasma cells. Also called “Free Lambda Light Chains” they link together with other proteins (heavy chains) to form immunoglobulins (= antibodies) that target and neutralize specific threats to the body (= bacteria & viruses). Plasma cells normally produce some excess light chains that do not combine with heavy chains and instead enter the bloodstream. Free light chains refer to those that are not part of whole (= intact) immunoglobulins and are present in the blood. This test measures the amount of free lambda light chains in the blood to help detect, diagnose, and monitor conditions associated with an increased production of free light chains. Each type of immunoglobulin is composed of four protein chains: 2 identical heavy chains and 2 identical light chains. A particular plasma cell will produce only one type of immunoglobulin. Normally, there is a slight excess of free light chains produced, so low levels of free kappa and lambda chains are detected in the blood. References: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629951/ https://labtestsonline.org/tests/serum-free-light-chains
Kappa/Lambda Light Chain, Free w/Ratio,Rand Urine
The Kappa/Lambda Light Chain, Free w/Ratio, Random Urine panel from Quest Diagnostics is a crucial diagnostic test for detecting and monitoring multiple myeloma and other disorders related to abnormal or excessive production of immunoglobulin light chains. This test measures the levels of kappa and lambda free light chains, along with their ratio, in urine. The precise quantification of these light chains and their ratio is essential for diagnosing conditions like light chain multiple myeloma or primary systemic amyloidosis. Quest Diagnostics, renowned for their advanced diagnostic technology and accuracy, ensures reliable results for this test, making it an invaluable tool for healthcare professionals in the early detection and management of these complex conditions. This test is also instrumental in monitoring the effectiveness of treatment regimens for patients with plasma cell dyscrasias, contributing significantly to patient care and outcomes.
Biomarkers in this category
7 biomarkers · optimal ranges shown
Kappa – Immunofixation, Serum (NMH/LFH) Marker name: Kappa Test panel: Immunofixation, Serum (NMH/LFH) Category: Immunoglobulin Light Chains / Monoclonal Gammopathy Screening What is Kappa? Kappa is one of two types of light chains (the other being lambda) found in immunoglobulins (antibodies), which are proteins produced by plasma cells in the immune system. Each antibody contains two heavy chains and two light chains—either kappa or lambda, but not both. In healthy individuals, kappa and lambda light chains are produced in a balanced ratio. An abnormal increase in one type may indicate the presence of a monoclonal protein (M-protein), a hallmark of certain plasma cell or B-cell disorders. Why is Kappa measured in serum immunofixation? Serum immunofixation electrophoresis (IFE) is used to identify abnormal monoclonal proteins in the blood. By specifically analyzing kappa and lambda light chains in conjunction with different immunoglobulin heavy chains (IgG, IgA, IgM, etc.), the test helps determine whether a monoclonal gammopathy is present, and what type of immunoglobulin is involved. This test is particularly useful for diagnosing and monitoring: Multiple myeloma Monoclonal gammopathy of undetermined significance (MGUS) Waldenström macroglobulinemia Primary amyloidosis (AL) Chronic lymphocytic leukemia (CLL) Other B-cell or plasma cell dyscrasias What does an abnormal Kappa result mean? Increased Kappa light chain (with or without decreased lambda) may indicate a monoclonal kappa light chain-producing clone, often seen in multiple myeloma, MGUS, or related conditions. A monoclonal band (also called an “M-spike”) corresponding to kappa in the presence of a specific heavy chain (e.g., IgG kappa) suggests a clonal population of plasma cells. Suppressed or absent Kappa may be relevant when lambda is elevated, suggesting a monoclonal lambda-producing disorder. The interpretation of kappa results always considers the kappa/lambda ratio, which helps assess the clonality of plasma cells and distinguish between benign polyclonal responses and malignant monoclonal proliferations. What follow-up testing might be needed? If a monoclonal kappa light chain is detected: Serum free light chain (FLC) assay to quantify free kappa and lambda chains and their ratio Serum protein electrophoresis (SPEP) to assess the M-protein concentration Urine immunofixation for Bence Jones protein (free light chains in urine) Bone marrow biopsy to evaluate plasma cell proliferation Imaging to assess for bone lesions (in multiple myeloma) Key takeaways Kappa is a type of immunoglobulin light chain analyzed in serum immunofixation. It helps detect monoclonal gammopathies and determine the type of abnormal antibody produced. Abnormal kappa results—especially with an altered kappa/lambda ratio—can be early markers of plasma cell disorders like multiple myeloma. Interpretation should always be made in the context of clinical findings and additional lab data.
can help diagnose multiple myeloma and other plasma cell dyscrasias
Kappa/Lambda Ratio – What It Means and Why It Matters The Kappa/Lambda ratio is a key marker used to evaluate the balance of free light chains—kappa and lambda—produced by plasma cells in the immune system. These light chains are components of antibodies, and under normal conditions, the body maintains a relatively stable ratio between them. An abnormal kappa/lambda ratio can be a strong indicator of a plasma cell disorder. A high ratio (above the normal range) suggests excess production of kappa light chains, possibly due to kappa-restricted monoclonal gammopathy, such as multiple myeloma or MGUS. A low ratio suggests an excess of lambda light chains, which may indicate lambda-restricted monoclonal gammopathy. When one light chain type is significantly elevated and the ratio is skewed, it usually points to a clonal proliferation of abnormal plasma cells producing only one type of light chain. The Kappa/Lambda ratio is especially useful in conjunction with serum free light chain testing and immunofixation electrophoresis to detect and monitor conditions like multiple myeloma, AL amyloidosis, and other B-cell malignancies.
help to detect and manage multiple myeloma and other plasma cell disorders
Lambda – Immunofixation, Serum (NMH/LFH) What is Lambda? Lambda refers to one of two types of light chains (the other being kappa) produced by plasma cells, a type of white blood cell responsible for making antibodies (immunoglobulins). Each antibody contains either kappa or lambda light chains, but not both. Measuring lambda light chains helps assess abnormal antibody production, which can be a sign of certain blood or bone marrow disorders. Why is Lambda Tested in Serum Immunofixation? The Immunofixation Electrophoresis (IFE) test identifies abnormal proteins (monoclonal immunoglobulins or M-proteins) in the blood. These are often produced in excess in disorders like: Multiple myeloma Monoclonal gammopathy of undetermined significance (MGUS) Waldenström’s macroglobulinemia Light chain amyloidosis (AL amyloidosis) The Lambda test specifically detects the presence of monoclonal immunoglobulins with lambda light chains. The panel also checks for immunoglobulin heavy chains (IgG, IgA, IgM) and kappa light chains to determine the exact type of monoclonal protein present. What Does an Abnormal Lambda Result Mean? Elevated or restricted lambda bands may indicate monoclonal lambda light chain production, often associated with plasma cell or B-cell malignancies. A predominant lambda band without a matching kappa band suggests a monoclonal gammopathy with lambda restriction. In contrast, a polyclonal increase in both kappa and lambda is usually a sign of inflammation or immune activation, not cancer. Normal vs. Abnormal Pattern Pattern Interpretation Polyclonal (kappa and lambda present in balance) Normal immune response Monoclonal (only lambda, sharp band) Possible plasma cell disorder (e.g., multiple myeloma) No detectable bands Normal or below detection threshold Clinical Follow-Up If a monoclonal lambda light chain is detected, additional tests may be ordered to determine: The quantity of monoclonal protein (via serum protein electrophoresis or free light chain assay) Bone marrow biopsy to evaluate plasma cell population Kidney function, since light chains can damage the kidneys Summary The Lambda marker on a Serum Immunofixation (IFE) panel helps identify abnormal antibody production associated with blood cancers and related disorders. When interpreted alongside kappa and heavy chain findings, it provides crucial information about the type and significance of any monoclonal protein detected.
The Lambda Light Chain, Free, Urine test is a critical diagnostic tool, prominently used in the field of medical diagnostics to identify and monitor various hematologic disorders, with a particular focus on multiple myeloma and other conditions related to plasma cell dyscrasias. This test specifically measures the concentration of free lambda light chains in the urine. Lambda light chains are protein fragments produced by plasma cells, a type of white blood cell integral to the immune system. An abnormal increase in the levels of lambda light chains in urine can be a key indicator of multiple myeloma, a cancer of plasma cells, or other related disorders such as light chain amyloidosis, where abnormal proteins accumulate in tissues. This test plays a vital role in the diagnosis and monitoring of these diseases, aiding in early detection and effective management.